

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 April 2003 (24.04.2003)

PCT

(10) International Publication Number
WO 03/033697 A1

(51) International Patent Classification⁷: C12N 15/09,
5/02, C12P 21/06

(21) International Application Number: PCT/US02/33304

(22) International Filing Date: 18 October 2002 (18.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/337,446 18 October 2001 (18.10.2001) US

(71) Applicant (for all designated States except US): IXION
BIOTECHNOLOGY, INC. [US/US]; 13709 Progress
Blvd., Box 13, Suite N-111, Alachua, FL 32615 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): YIN, Li [CN/US];
1111 S.W. 16th Ave., #68, Gainesville, FL 32601 (US).

(74) Agents: SWANSON, Barry, J. et al.; Swanson &
Bratschun, L.L.C., Suite 330, 1745 Shea Center Drive,
Highlands Ranch, CO 80129 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 03/033697 A1

(54) Title: CONVERSION OF LIVER STEM AND PROGENITOR CELLS TO PANCREATIC FUNCTIONAL CELLS

(57) Abstract: The subject invention a method for converting liver stem/progenitor cells to a pancreatic functional cell by transfect-
ing said liver cells with a pancreatic development gene and/or by culturing with pancreatic differentiation factors. The resulting cells
produce and secrete insulin protein in response to glucose stimulation.

BEST AVAILABLE COPY

CONVERSION OF LIVER STEM AND PROGENITOR CELLS TO PANCREATIC FUNCTIONAL CELLS

BACKGROUND

Cell transplantation as a cure or treatment for diabetes.

Type I diabetes is a chronic metabolic disease caused by selective autoimmune destruction of insulin-producing islet β -cells. Clinical management of diabetes costs ~\$100 billion annually in this country. The insulin insufficiency and hyperglycemia of type I diabetes, in the long run, lead to serious secondary complications. Regular insulin replacement therapy that is being used to control daily glucose fluctuations, however, does not maintain glucose levels near-normal range at all times to prevent/reduce clinical complications (The DCCT Research Group (1991) N. Eng. J. Med. 329:977).

To cure or treat type I diabetes (both in terms of achieving insulin independence and reducing the incidence of secondary complications), it is essential to restore islet β -cells in the patients either as whole pancreas or islet transplantation. Only about 3,000 cadaver pancreata become available in the US each year while ~ 35,000 new cases of type I diabetes are diagnosed during the same period of time (Hering, G.J. et al. (1999) Graft 2:12-27). Thus, there is an urgent need to develop alternate sources of functional cells of pancreatic lineage, including islets and/or insulin-producing cells. The only conceptual option available to circumvent the severe shortage of pancreatic tissue for transplantation is to develop functional cells of pancreatic lineage (e.g., islets or insulin-producing cells) *in vitro* from stem cells.

One source of transplantable islets is pancreas-derived islet producing stem cells (IPSCs) (Ramiya, V.K. et al. (2000) Nature Med. 6(3):278-282; and PCT/US00/26469, filed September 27, 2000). However, additional/alternative methods of generating pancreatic lineage cells should be investigated to increase the chances of success in attempts to cure or treat type I diabetes. Liver stem/progenitor cells offer a feasible source for conversion into pancreatic lineage cells. There are many advantages of using liver stem cells: a) liver has the immense potential to regenerate following partial hepatectomy (for instance, the mass and function of the partially hepatectomized liver can be totally restored in about a week, even if 2/3 of liver is resected (Higgins, G.F. et al. (1931) Arc. Pathol. 12:186-202; Grisham, J.W.

(1962) Cancer Res. 22:842-849; and Bucher, N. (1963) Int. Rev. Cytol. 15:245-300)), and therefore, liver provides a more easily accessible source of stem cells for autologous transplantation; and b) the surface phenotype of liver stem cells have already been established and hence it is easier to purify them from the organ (see Table 1). Also liver stem cells share surface hematopoietic stem cell markers like CD34, Thy1.1, stem cell factor(SCF)/c-kit, Flt-3 ligand/flt-3 (Yin, L. et al. (2001) Proc. Am. Assoc. Canc. Res. 42:354; Yin, L. et al. (2001) FASEB J. Late-Breaking Abstracts:49 (LB267); Fujio, K. et al. (1996) Exp. Cell Res. 224:243-50; Blakolmer, K. et al. (1995) Hepatology 21(6):1510-16; Omori, N. et al. (1997) Hepatology 26(3):720-27; Omori, M. et al. (1997) Am. J. Pathol. 150(4):1179-87; Lemmer, E.R. et al. (1998) J. Hepatol. 29:450-454; Petersen, B.E. et al. (1998) Hepatology 27(2):433-445; and Baumann, U. et al. (1999) Hepatology 30(1):112-117), which can be used for cell sorting along with other known liver stem cell markers.

Markers	Hepatoblasts	Oval cells	Hepatocytes	Bile duct cells
<u>CK19</u>	±	±	=	±
<u>CK14</u>	±	±	=	=
<u>Albumin</u>	±	+/-	±	=
<u>AFP</u>	±	±	=	=
<u>GGT</u>	±	±	=	±
<u>OV6</u>	±	±	=	±
<u>OV1</u>	±	±	=	±
<u>BD1</u>	=	=	=	±
<u>HES6</u>	=	=	±	=
<u>OC.2</u>	±	±	=	±
<u>OC.3</u>	±	±	=	±
<u>OC.10</u>	±	±	=	±
<u>H.1</u>	=	=	±	=
<u>H.4</u>	=	=	±	=

Table 1 Markers of development, differentiation and cell lineage specification of liver epithelial cells (Adapted from Grisham et al. (1991) in Stem Cells, C.S. Potter (ed.), Academic Press, San Diego, CA, pp. 233-82, with modifications).

The following sections describe the current status of liver and pancreatic stem cells, their relationship during embryonic development and transdifferentiation within these organs.

Development of liver and liver stem cells.

In the embryo, liver buds from epithelial cells of the ventral foregut in the region that is in contact with the precardiac mesoderm, at approximately 8.5 to 9 days of development in the mouse. The cells of this region proliferate to form the liver diverticulum. At about 9.5 days of gestation, cells of the liver diverticulum begin to migrate into the surrounding septum transversum. At this stage, the cells are designated as hepatoblasts, to indicate that these cells have been determined along the hepatic epithelial cell lineage. The hepatoblast has bipotential capability, and gives rise to both hepatocytes and bile duct cells (Houssaint, E. (1980) *Cell Differ.* 9:269-279). In general, when the liver is injured, the mature hepatocytes proliferate to restore the mass and function of the liver, and the liver stem cells are not involved (Kelly, D.E. et al. (1984) in *Bailey's Textbook of Microscopic Anatomy*, 18th ed., Williams and Wilkins, Baltimore, pp. 590-616). However, when the injury is too severe and/or the proliferation of hepatocytes is inhibited by chemicals such as 2-N-acetylaminofluorene (2AAF) and phenobarbital, the liver stem cell compartment is activated. Liver stem cells in the adult liver have been extensively studied mainly in the animal liver injury models, such as 2AAF/partial hepatectomy (PH) (Golding, M. et al. (1995) *Hepatology* 22(4):1243-1253), 2AAF/allyl alcohol (AA) and phenobarbital/cocaine leading to periportal liver injury (Yavokovsky, L. et al. (1995) *Hepatology* 21(6):1702-12; Petersen, B. et al. (1998) *Hepatology* 27(4):1030-1038; Yin, L. et al. (1999) *J. Hepatology* 31:497-507; and Rosenberg, D. et al. (2000) *Hepatology* 31(4):948-955), and 2AAF/CCl₄ inducing pericentral liver injury (Petersen et al. (1998)). Irrespective of the injury site, the oval shaped liver stem cells always originate in the portal area of canals of Hering (Wilson, J. et al. (1958) *J. Pathol. Bacteriol.* 76:441-449). These liver progenitor cells in adult liver can differentiate into both hepatocytes and bile duct cells (Stenberg, P. et al. (1991) *Carcinogenesis* 12:225-231; and Dabeva, J. et al. (1993) *Am. J. Pathology* 143:1606-1620). Most recently, several lines of evidence from both animals and humans strongly suggest that hematopoietic stem cells are the extrahepatic source of liver stem cells (Petersen, B. et al. (1999) *Science* 284:1168-70; Theise, N. et al. (2000) *Hepatology* 31(1):235-40; Theise, N. et al. (2000) *Hepatology* 32(1):11-16; and Alison, M. et al. (2000) *Nature* 406:257). Epithelial cell lines with stem-like properties have been established from mouse liver diverticulum (Rogler, L. (1997) *Am. J. Pathol.* 150(2):591-602), injured rat liver (Yin, L. et al. (2001A) *PAACR* 42:354; Yin, L. et al. (2001B) *FASEB J. Late-Breaking Abstracts*:49 (LB267); Yin, L. et al. (2002) *Hepatology* 35(2):315-324), and normal rat (Tso,

M-S. et al. (1984) *Exp. Cell. Res.* 154:38-52; and Tso, M-S. (1988) *Lab. Invest.* 58:636-642), porcine (Kano, J. et al. (2000) *Am. J. Pathol.* 156(6):2033-2043), and human liver (Crosby, H. et al. (2001) *Gastroenterology* 120(2):534-544). These cells can be induced to differentiate into hepatocytes and/or bile duct cells *in vitro* (Rogler, L. (1977); Yin, L. et al. (2001A); Yin, L. et al. (2001B); Yin, L. et al. (2002); Crosby, H. et al. (2001); and Coleman, W. et al. (1993) *Am. J. Pathol.* 142:1373-82) and *in vivo* upon transplantation (Coleman, W. et al. (1993); and Grisham, J. et al. (1993) *Proc. Soc. Exp. Biol. Med.* 204:270-79).

The signaling molecules that elicit embryonic induction of the liver from the mammalian gut endoderm are not fully understood. Fibroblast growth factors (FGFs) 1, 2, and 8 expressed in the cardiac mesoderm are reported to be essential for the initial hepatogenesis (Jung, J. et al. (1999) *Science* 284:1998-2003). Oncostatin M (OSM), an interleukin-6 family cytokine, in combination with glucocorticoid, induces maturation of hepatocytes in embryonic liver, which in turn terminate embryonic hematopoiesis. Livers from mice deficient for gp130, an OSM receptor subunit, display defects in maturation of hepatocytes (Kamiya, A. et al. (1999) *EMBO J.* 18(8):2127-36; and Kinoshita, T. et al. (1999) *PNAS* 96:7265-70). Differentiated hepatocytes are characterized by the expression of a unique combination of liver-enriched (but not liver-unique) transcription factors of *HNF1*, *HNF3*, *HNF4*, and *C/EBP* families (Johnson, P. (1990) *Cell. Growth Differ.* 1:47-51; Lai, E. et al. (1991) *Trends Biochem. Sci.* 16:427-30; DeSimone, V. et al. (1992) *Biochem. Biophys. Acta* 1132:119-126; and Crabtree, G. et al. (1992) in *Transcriptional Regulation*, S.S. McKnight and K.R. Yamamoto (eds.) Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp. 1063-1102).

Development of pancreas and pancreatic stem cells.

During embryonic development, the pancreas derives from two separate outgrowths of dorsal and ventral foregut endoderm to form dorsal and ventral buds. These buds then fuse to form the definitive pancreas (Houssaint, E. (1980); Spooner, B. et al. (1970) *J. Cell Biol.* 47:235-46; Rutter, W. et al. (1980) *Monogr. Pathol.* 21:30-38; Guaidi, R. et al. (1996) *Genes Dev.* 10:1670-82; Zaret, K. (2000) *Mech. Dev.* 92:83-88; Edlund, H. (1998) *Diabetes* 47:1817-1823; St-Onge, L. et al. (1999) *Curr. Opin. Gene Dev.* 9:295-300; and Slack, J. (1995) 121:1569-80). During embryogenesis, islet development within the pancreas appears to be initiated from undifferentiated precursor cells associated primarily with the pancreatic ductal epithelium (Pictet, R. et al. (1992) in *Handbook of Physiology*, Steiner, D. and Frienkel, N. (eds.) Williams and Wilkins, Baltimore, MD, pp. 25-66). This ductal epithelium rapidly

proliferates, and then subsequently differentiates into the various islet-associated cell populations (Teitelman, G. et al. (1993) *Development* 118:1031-39; and Beattie, G. et al. (1994) *J. Clin. Endo. Met.* 78:1232-1240). In the adult pancreas, the islet cell growth can occur through two different pathways: either by growth of new islets by differentiation of ductal epithelium (neogenesis), or by replication of preexisting β -cells. Neogenesis has been induced experimentally by dietary treatment with soybean trypsin inhibitors (Weaver, C. et al. (1985) *Diabetologia* 28:781-785), high level of interferon- γ (Gu, D. (1993) *Dev.* 118:33-46), partial pancreatectomy (Bonner-Weir, S. et al. (1993) *Diabetes* 42:1715-1720), wrapping of the head of the pancreas in cellophane (Rosenberg, L. et al. (1992) *Adv. Exp. Med. Biol.* 321:95-104), and by specific growth factors (Otonkanski, T. et al. (1994) *Diabetes* 43:947-952). Thus, it is generally accepted that all endocrine cell types of the pancreatic islets arise from the same ductal epithelial stem cell through sequential differentiation (Gu, D. (1993); Rosenberg, L. (1992); and Hellerstrom, D. (1984) *Diabetologia* 26:393-400). Pancreatic stem cells have been isolated from adult pancreatic ductal preparations, and have been shown to differentiate (to some degree) into insulin-producing cells *in vitro* (Ramiya, V. et al. (2000); Cornelius, J. et al. (1997) *Horm. Metab. Res.* 29:271-277; and Bonner-Weir, S. et al. (2000) *PNAS* 97(14):7999-8004), which upon transplantation, were able to reverse diabetes in non-obese diabetic (NOD) mice (Ramiya, V. et al. (2000)).

During embryonic development, there are differences in the specification of the dorsal and ventral pancreatic rudiments. The dorsal pre-pancreatic endoderm remains closely associated with the notochord during early developmental stages. Signals derived from overlaying notochord, such as activin and FGF-2, promote dorsal pancreas development by repressing endodermal expression of sonic hedgehog (*Shh*) (Hebrok M. et al. (2000) *Dev.* 127:4905-13; Kim, S. et al. (1997) *Dev.* 124:4243-52; and Li, H. et al. (1999) *Nat. Genet.* 23:67-70). Generation of a dorsal pancreas in response to these signaling events also requires the expression of a number of transcription factors. For example, mouse 'knockout' studies have shown that formation of the dorsal pancreas is dependent on *Isl1* and *Hlxb9*, and that subsequent differentiation requires *Pdx1* (Li, H. et al. (1999); Harrison, K. et al. (1999) *Nat. Genet.* 23:71-75; Ahlgren, U. et al. (1997) *Nature* 385:257-60). The mechanisms regulating the onset of ventral pancreas development are not fully defined. The control of ventral pancreatic development would differ from that of dorsal pancreas because the notochord does not extend as far as ventral endoderm, and by default, the ventral endoderm does not express *Shh*. Moreover, ventral pancreatic development is normal in *Isl1* $-/-$ and *Hlxb9* $-/-$ mice (Deutsch, G.

et al. (2001) Development 128:871-881; and Duncan, S. (2001) Nature Genetics 27:355-356). *Pdx1* is required at an earlier stage in pancreas development (Jonsson, J. et al. (1994) Nature 371:606-609; Ahlgren, U. et al. (1996) Development 122:1409-1416; Stoffers, D. et al. (1997) Nat. Genet. 15:106-110; and Offield, M. et al. (1996) Development 122:983-995). Mice and humans lacking *Pdx1* are apancreatic (Jonsson, J. et al. (1994); Ahlgren, U. et al. (1996); Stoffers, D. et al. (1997); and Offield, M. et al. (1996)). However, there seems to be other genes that act upstream of *Pdx1* expression for the initial commitment of the gut endoderm to a pancreatic fate. Accordingly, the evagination of the epithelium and the initial commitment of dorsal and ventral pancreatic buds still take place in *Pdx1* mutant mice, and insulin- and glucagon-positive cells still differentiate (Ahlgren, U. et al. (1996); and Offield, M. et al. (1996)). Later, *Pdx1* and *Hlxb9* expression in the pancreas become restricted to the insulin-producing β -cells (Li, H. et al. (1999); Harrison, K. et al. (1999); and Jonsson, J. et al. (1994)). *Pdx1* is required for maintaining the hormone-producing phenotype of the β -cell by regulating the expression of a variety of endocrine genes, including insulin, GLUT2, glucokinase, and prohormone convertases (PC) 1, 2, and 3 (Ahlgren, U. et al. (1998) Genes Dev. 12:1763-68; Hart, A. et al. (2000) Nature 408:864-68; and Baeza, N. et al. (2001) Diabetes 50, Sup. 1:S36). The *Pdx1* gene activation may be regulated by *HNF3 β* (Zaret, K. (1996) Annu. Rev. Physiol. 58:231-251) and *NeuroD/ β 2* (Sharma, T. et al. (1997) Mol. Cell Biol. 17:2598-2404). Several homeodomain and basic helix-loop-helix (bHLH) transcription factors like *ngn3*, *Isl1*, *Nkx2.2*, *Nkx6.1*, *Pax4*, *Pax6*, and *NeuroD/ β 2*, have been shown to play an important role in the control of pancreatic endocrine cell differentiation (Edlund, H. (1998); St-Onge, L. et al. (1999); Sander, M. et al. (1997) J. Mol. Med. 75:327-340; Madsen, O. et al. (1997) Horm. Metab. Res. 29(6):265-270; and Gradwohl, G. et al. (2000) PNAS 97(4):1607-11). Of these genes, *ngn3* has been reported to be critical for the development of all four endocrine cell lineages of the pancreas (Gradwohl, G. et al. (2000)). *Pax4* appear to selectively control the development of insulin-producing β -cells and somatostatin-producing δ -cells (Sosa-Pineda, B. et al. (1997) Nature 386:399-402). *Nkx6.1* has a highly restricted β -cell expression in the adult rat (Madsen, O. et al. (1997)). Disruption of *Nkx6.1* in mice leads to loss of β -cell precursors and blocks β -cell neogenesis (Sander, M. et al. (2000) Dev. 127(24):5533-5540). Thus, it is essential to screen for these factors following differentiation procedures to determine the extent of differentiation.

Various growth factors, hormones, vitamins and chemicals, such as hepatocyte growth factor (HGF), glucagon-like peptide-1 (GLP-1), exendin-4, activin-A, β -cellulin,

dexamethasone, nicotinamide, and sodium butyrate, have been shown to be effective in β -cell differentiation *in vitro*. HGF (Mashima, H. et al. (1996) *Endocrinol.* 137:3969-76), GLP-1 (Zhou, J. et al. (1999) *Diabetes* 48:2358-2366), exendin-4 (Zhou, J. et al. (1999)), dexamethasone, β -cellulin and activin-A (Mashima, H. et al. (1996) *J. Clin. Invest.* 97(7):1647-54) differentiate acinar cells into insulin-secreting cells. GLP-1 increases levels of β -cell cAMP and insulin gene transcription and stimulates glucose-dependent insulin release (Grucker, D. et al. (1987) *PNAS* 84:3434-3438). Administration of GLP-1 for 10 days to neonatal diabetic rats following partial pancreatectomy stimulated expansion of β -cell mass *via* induction of islet proliferation and neogenesis (Xu, G. et al. (2000) *Diabetes* 48:2270-76). GLP-1 also increases *Pdx1* gene expression and binding capacity (Buteau, J. et al. (1999) *Diabetes* 49:1156-1164). Exendin-4 is a potent structural analog of GLP-1, and has a longer circulating half-life. It binds to GLP-1 receptor on islets with similar affinity to GLP-1, but increases cAMP levels 3-fold higher than GLP-1 at equimolar concentrations, making it a more effective agent for use in chronic animal studies (Garcia-Ocana, A. et al. (2001) *JCE & M* 86:984-988). Dexamethasone and sodium butyrate might promote β -cell differentiation as evidenced by increased insulin/DNA contents in porcine pancreatic islet-like cell clusters (Korsgren, O. et al. (1993) *Ups. J. Med. Sci.* 98(1):39-52). In pancreas cell line, RIN-m5F, sodium butyrate increases 2-fold both hexokinase and glucokinase activities, as well as, the glucokinase gene expression. Nicotinamide is a poly (ADP-ribose) synthetase inhibitor known to differentiate and increase β -cell mass in cultured human fetal pancreatic cells and mouse IPSCs (Ramiya, V. et al. (2000); and Otonkoski, T. et al. (1993) *J. Clin. Invest.* 92:1459-66) and prevents the development of diabetes in drug induced diabetic animal models as well as in the NOD mice (Uchigata, Y. et al. (1983) *Diabetes* 32:316-18; and Yamada, K. et al. (1982) *Diabetes* 31:749-753).

Manipulation of pancreatic stem and liver stem cell differentiation.

In embryonic development, the liver and ventral pancreas both originate from the same location in the ventral foregut (Houssaint, E. (1980); Rutter, W. (1980); Guaidi, R. et al. (1996); Zaret, K. (2000); Deutsch, G. et al. (2001); and Zaret, K. (1996)). Therefore, it is possible, from the developmental point of view, that epithelial cells in these two organs may share common stem cells. A new study shows that a bipotential cell population exists in the embryonic endoderm that gives rise to both the liver and the pancreas. The decision by these cells to adopt either a pancreatic or hepatic cell fate is determined by their proximity to the

developing heart (Deutsch, G. et al. (2001)). The default developmental program of the ventral endoderm is to become ventral pancreas. Several lines of evidence have attested to the ability of pancreatic stem cells to differentiate into liver cell. For instance, copper depletion and repletion result in the atrophy of exocrine pancreas and the appearance of oval cells within the pancreatic ducts which then differentiate into hepatocytes within the pancreas (Rao, M. et al. (1986) Cell Differ. 18:109-117; Rao, M. et al. (1988) Biochem. Biophys. Res. Commun. 156:131-136; and Reddy, J. et al. (1991) Dig. Dis. Sci. 36(4):502-509). Oval cells with immunophenotype identical to hepatic stem cells were also found in human pancreas with acute pancreatitis, chronic pancreatitis, and pesidioblastosis (Mikami, Y. et al. (1998) Hepatology 28(4), Pt. 4:417A). The pancreatic hepatocytes respond to the carcinogens in a fashion similar to liver hepatocytes (Rao, M. et al. (1991) Am. J. Pathol. 139(5):1111-1117). Following transplantation into the liver, pancreatic oval cells isolated from copper-deficient rat pancreas can differentiate into mature hepatocytes with structural integration in the hepatic parenchyma and expression of biochemical functions unique to the hepatocytes (Dabeva, J. et al. (1997) PNAS 94:7356-61). Most recently, Wang and coworkers demonstrated the existence of undifferentiated progenitors of hepatocytes in the pancreas of normal adult mouse (Wang, X. et al. (2001) Am. J. Pathol. 158:571-79). Pancreatic cells can also be converted into hepatocytes *in vitro* by treatment with dexamethasone (Shen, C-N. et al. (2000) Nature Cell Biol. 2:879-887). The initial events involve activation of the transcriptional factor *C/EBP-β*. Transfection of cells with *C/EBP-β* brings about hepatic differentiation. Therefore, *C/EBP-β* is suggested as a key component that distinguishes the liver and pancreatic programs of differentiation. The consistent development of pancreatic hepatocytes in transgenic mice overexpressing KGF driven by insulin promoter indicates the involvement of KGF in the transdifferentiation process (Krakowski, M. et al. (1999) Am. J. Pathol. 154(3):683-91). Although not specific to endocrine cells, there is also a report on the ability of liver to generate pancreatic epithelial cells (Rao, M. et al. (1986) Histochem. Cytochem. 34:197-201; and Bisgaard, H. et al. (1991) J. Cell Physiol. 147(2):333-343). Further, liver transduced with recombinant-adenovirus carrying gene encoding *Pdx1* can produce functional insulin and ameliorates streptozotocin-induced diabetes in mice; however, *Pdx1* is reported to not transdifferentiate liver hepatocytes to insulin producing cells *in vitro*, and no evidence is provided that mouse liver stem or progenitor cells are transfected *in vivo* (or *in vitro*) with the *Pdx1* construct (Ferber, S. et al. (2000) Nature Med. 6(5):568-571). Finally, while sharing of transcription factors such as *Isl1*, *ngn3*, *NeuroD/β2*, *Pax4*, *pax6*, and *Nkx2.2*, between

endocrine and neuronal differentiation pathways has been established (Ahlgren, U. et al. (1997); Sander, M. et al. (1997); Sosa-Pineda, B. et al. (1997); Pfaff, S. et al. (1996) Cell 84:309-320; Lee, J. et al. (1995) Science 268:836-844; Naya, F. et al. (1997) Genes Dev. 11:2323-2334; Miyata, T. et al. (1999) Genes Dev. 13:1647-52; St-Onge, L. et al. (1997) Nature 387:406-409; Ericson, J. et al. (1997) J. Cell 90:169-180; Sussel, L. et al. (1998) Dev. 125:2213-2221; Briscoe, J. et al. (1999) Nature 398:622-627), there is no clear information on the sharing of transcription factors between liver and pancreas.

SUMMARY OF THE INVENTION

The subject invention comprises methods of culturing liver stem/progenitor cells with combinations of hormones, growth factors, vitamins and chemicals to convert the liver stem or progenitor cells to pancreatic functional cells. It further comprises transfection methods for conversion of liver stem or progenitor cells to pancreatic functional cells.

Thus, the invention provides a method for converting a liver stem/progenitor cell to the pancreatic functional cell by transfecting the liver stem/progenitor cell with a pancreatic development gene. Alternatively, the liver stem/progenitor cell may be cultured under conditions that convert the cell to the pancreatic functional cell. Further, conversion can be achieved by both transfection and culture conditions, effected simultaneously or sequentially in either order.

The liver stem/progenitor cell can be a hepatoblast or a liver oval cell. It is preferred that the liver stem/progenitor cell express at least one hematopoietic marker and/or at least one liver oval or hepatoblast cell marker. The hematopoietic markers include CD34, Thy1.1 and CD45. The liver hepatoblast or oval cell markers include α -fetal protein, albumin, cytokeratin 14 (CK14), c-kit, OC.2, OC.3, OC.10, OV1 and OV6.

The pancreatic development gene is any gene that is capable of converting liver stem/progenitor cells to pancreatic functional cells, and includes *Pdx1*, *Hlxb9*, *Isl1*, *ngn3*, *Nkx2.2*, *Pax6*, *NeuroD/β2*, *Nkx6.1* and *Pax4*. Preferably, the pancreatic development gene is *Pdx-1*.

Culture conditions that convert liver stem/progenitor cells to the pancreatic functional cells comprise basal medium plus the added factors of hormones, growth factors, vitamins and chemicals or any combination thereof that induce differentiation into pancreatic cells. Such hormones include dexamethasone, glucagon-like peptide-1 (GLP-1), and exendin-4; growth factors include gastrin, interferon- γ (IFN γ), hepatocyte growth factor (HGF), epidermal growth factor (EGF), β -cellulin, activin-A, keratinocyte growth factor (KGF), fibroblast growth factor

(FGF), transforming growth factor- α (TGF- α), transforming growth factor- β (TGF- β), nerve growth factor (NGF), insulin-like growth factors (IGFs), islet neogenesis associated protein (INGAP), and vascular endothelial growth factor (VEGF); vitamins include nicotinamide and retinoic acid; and chemicals include sodium butyrate.

According to this method, the liver stem/progenitor cell that is converted can express any combination of a number of pancreatic messenger RNAs, including insulin I (InsI), insulin II (InsII), glucagon, somatostatin, pancreatic polypeptide (PP), amylase, elastase, glucose transporter 2 (GLUT2), glucokinase, PC1, PC2, PC3, carboxypeptidase E (CPE), Pdx1, Hlxb9, Isl1, ngn3, Nkx2.2, Pax6, NeuroD/ β 2, Nkx6.1 and Pax4. Likewise, the converted cell may express any combination of a number of pancreatic proteins including InsI, InsII, glucagon, somatostatin, PP, amylase, elastase, GLUT2, glucokinase, PC1, PC2, PC3, CPE, Pdx1, Hlxb9, Isl1, ngn3, Nkx2.2, Pax6, NeuroD/ β 2, Nkx6.1 and Pax4.

Preferably, the converted liver stem/progenitor cell differentiates into the pancreatic endocrine pathway. Such converted cells can be cultured to produce endocrine hormones (e.g., insulin, glucagon and somatostatin from β , α and δ cells).

The method of conversion via transfection with a pancreatic development gene or via culture conditions may result in pancreatic cells at different stages of differentiation, including islet producing stem cells (IPSCs), islet progenitor cells (IPCs) and islet-like structures or IPC-derived islets (IdIs), or cellular components thereof (α , β , δ and/or PP cells).

Transdifferentiation may also result in a cell that manifests expression patterns of a pancreatic cell (e.g., insulin production), and that may also retain characteristics of the liver stem/pancreatic cell (e.g., liver stem or progenitor markers). Liver stem/progenitor cell markers include hematopoietic markers and liver oval or hepatoblast cell markers.

All references cited herein are incorporated in their entirety by reference.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 sets forth the characterization of five liver epithelial cell lines derived from allyl alcohol-injured rat liver. The meaning of symbols is: - negative, +/- weakly positive, + positive, ++ strongly positive.

Figure 2 illustrates the bipotentiality of liver epithelial line 3(8)#21 to differentiate into hepatocyte-like and bile duct-like cells. A: 3(8)#21 cultured without feeder are positive for mature hepatocyte marker H4. B: on day 6, 3(8)#21 cultured without feeder are positive for mature hepatocyte marker CYP1AII on day 12. C: 3(8)#21 cultured without feeder but with

bFGF; more H4 positive cells observed on day 6. D: 3(8)#21 cells cultured on matrigel without feeder form ductular structure on day 4. E: 3(8)#21 cells cultured on matrigel without feeder express strongly mature bile duct cell marker BD1 on day 13. The magnification is 400x for panels A, B, C, and E. The magnification is 200x for panel D (Yin, L. et al. (2001A); Yin et al. (2001B); and Yin, L. et al. (2002)).

Figure 3 shows the expression of pancreatic development markers in five liver stem/progenitor cell lines.

Figure 4 illustrates the expression of insulin II and amylase in the liver progenitor lines after transfection with the *Pdx1* gene.

DETAILED DESCRIPTION

To facilitate a further understanding of the invention, the following definitions are provided.

"Islet producing stem cell" (IPSC) refers to those stem cells that arise from or among pancreatic ductal epithelium *in vitro* and *in vivo*. Methods for obtaining and maintaining IPSCs are described in detail in PCT/US00/26469, filed September 27, 2000, which incorporated herein in its entirety by reference.

"Islet progenitor cell" (IPC) refers to pancreatic progenitor cells that arise from IPSCs cultured *in vitro* using methods described herein and in PCT/US00/26469.

"IPC-derived islet" (IdI) refers to the islet-like structures that arise from IPCs cultured *in vitro* using methods described herein and in PCT/US00/26469.

"Liver stem/progenitor cell" refers to all liver stem and/or progenitor cells, including without limitation, hepatoblasts, oval cells, liver epithelial cells with stem-like properties, and de-differentiated hepatocytes and bile duct cells. While many liver stem/progenitor lines have been reported in the literature (Williams, G. et al. (1971) Exp. Cell Res. 69:106-112; Williams, G et al. (1973) 29:293-303; Grisham, J. (1980) Ann. N.Y. Acad. Sci. 349:128-137; Tsao, M-S. et al. (1984) Exp. Cell Res. 154:38-52; Coleman, W. et al. (1997) Am. J. Pathol. 151:353-359; Coleman, W. et al. (1993) Am. J. Pathol. 142:1372-82; McCullough, K. et al. (1994) Cancer Res. 54:3668-71; Amicone, L. et al. (1997) EMBO J. 16:495-503; Spagnoli, F. et al. (1998) J. Cell Biol. 143:1101-1112; Sell, S. et al. (1982) Hepatol. 2:77-86; Shinozuka, H. et al. (1978) Cancer Res. 38:1092-98; McMahon, J. et al. (1986) Cancer Res. 46:4665-71; Brill, S. et al. (1999) Digest. Dis. Sci. 44:364-71; and Rogler, L. (1977) Am. J. Pathol. 150:591-602), preferably, the liver stem/progenitor cells used in the subject methods are obtained from liver

injury models without the involvement of carcinogens, as described for example in Yin, L. et al. (2001A), Yin, L. et al. (2001B) and Yin, L. et al. (2002). It is also preferred that the liver stem/progenitor cells express one or more of the liver oval or hepatoblast cell markers (α -fetal protein, albumin, cytokeratin 14 (CK14), c-kit, OC.2, OC.3, OC.10, OV1 and OV6), and/or one or more of the hematopoietic stem markers (CD34, Thy1.1 and CD45).

"Pancreatic endocrine lineage" refers to commitment to development into pancreatic endocrine cells.

"Pancreatic lineage" refers to commitment to development into pancreatic cells including endocrine, exocrine and/or duct cells.

"Pancreatic functional cells" refers to cells of the pancreatic lineage or cells that have been transdifferentiated or converted according to methods described herein, and which express mRNA or proteins that are characteristic of and specific to a pancreatic cell (e.g., insulin), and which may also retain characteristics of the liver stem/pancreatic cell (i.e., liver stem or progenitor markers). The pancreatic functional cell preferably is a glucose-responsive, insulin producing cell. It preferably produces and secretes insulin protein in response to glucose stimulation. The response is preferably within the normal range of insulin response for the mammalian species of interest. Such normal ranges are known in the art or are readily determinable.

"Transfection" refers to any method known in the art by which a fragment or construct of nucleic acid containing a coding sequence may be introduced into a target cell (here, a liver stem/progenitor cell) resulting in the expression of the coding sequence in the target cell. Included within the fragment or construct are the requisite promoter and regulatory sequences for expression in the target cell.

Thus, the subject invention comprises a method of converting a liver stem/progenitor cell to a pancreatic functional cell, by transfecting the liver stem/progenitor cell with a pancreatic development gene, and/or by culturing said liver stem/progenitor cell in a medium comprising factors that induce differentiation into the pancreatic functional cell. The resulting pancreatic functional cell can be a cell of the pancreatic endocrine lineage, or can be a cell having an expression pattern that is intermediate between the liver stem/progenitor cell and cells of pancreatic lineage. The term "cells of the pancreatic lineage" means islet producing stem cells (IPSCs), islet progenitor cells (IPCs), islet-like structures or IPC-derived islets (IdIs), or naturally derived pancreatic endocrine cells (e.g., α , β and/or δ cells, or duct cells). Additionally, cells having an intermediate expression pattern are those that produce and secrete

insulin protein in response to glucose stimulation, and which may express a marker of the liver stem/progenitor cell.

The liver stem/progenitor cells can be hepatoblasts and/or liver oval cells. The liver stem/progenitor cell expresses at least one hematopoietic marker and/or at least one liver oval or hepatoblast cell marker. The hematopoietic markers are CD34, Thy1.1 and/or CD45. The hepatoblast or oval cell markers α -fetal protein, albumin, cytokeratin 14 (CK14), c-kit, OC.2, OC.3, OC.10, OV1 and/or OV6.

In the transfection embodiment, the pancreatic development gene can be *Pdx1*, *Hlxb9*, *Isl1*, *ngn3*, *Nkx2.2*, *Pax6*, *NeuroD/β2*, *Nkx6.1* and/or *Pax4*. Preferably, the pancreatic development is *Pdx-1*.

In the culture transdifferentiation embodiment, liver stem/progenitor cells are cultured under methods known in the art in a standard medium plus factors. The factors include dexamethasone, glucagon-like peptide-1 (GLP-1), exendin-4, gastrin, interferon- γ (IFN γ), hepatocyte growth factor (HGF), epidermal growth factor (EGF), β -cellulin, activin-A, keratinocyte growth factor (KGF), fibroblast growth factor (FGF), transforming growth factor- α (TGF- α), transforming growth factor- β (TGF- β), nerve growth factor (NGF), insulin-like growth factors (IGFs), islet neogenesis associated protein (INGAP), vascular endothelial growth factor (VEGF), nicotinamide, retinoic acid, sodium butyrate or any combination thereof.

The converted cell can express any of a number of pancreatic messages including insulin I (InsI), insulin II (InsII), glucagon, somatostatin, pancreatic polypeptide (PP), amylase, elastase, glucose transporter 2 (GLUT2), glucokinase, PC1, PC2, PC3, carboxypeptidase E (CPE), *Pdx1*, *Hlxb9*, *Isl1*, *ngn3*, *Nkx2.2*, *Pax6*, *NeuroD/β2*, *Nkx6.1* and/or *Pax4*. Accordingly, the converted cell can express pancreatic proteins including InsI, InsII, glucagon, somatostatin, PP, amylase, elastase, GLUT2, glucokinase, PC1, PC2, PC3, CPE, *Pdx1*, *Hlxb9*, *Isl1*, *ngn3*, *Nkx2.2*, *Pax6*, *NeuroD/β2*, *Nkx6.1* and *Pax4*. It is preferred, however, that the converted cell produce and secrete insulin protein in response to glucose stimulation. The response is preferably within normal range for the mammalian cell of interest.

The subject invention also comprises a pancreatic functional cell produced by the methods described herein, wherein the pancreatic functional cell has an expression pattern that is intermediate between that of the liver stem/progenitor cell and cells of pancreatic lineage. In one embodiment, the pancreatic functional cell expresses *Pdx1*, amylase and insulin II.

The invention further comprises a method for producing an endocrine hormone comprising converting the liver stem/progenitor cells to pancreatic functional cells as described herein, culturing said pancreatic functional cells using methods known in the art and recovering endocrine hormone from the cell culture using methods known in the art.

EXAMPLES

Example 1 - Liver Stem/Progenitor Cells

Liver epithelial cell lines with liver stem cell properties were developed from allyl alcohol (AA)-injured adult rat liver as described in Yin, L. et al. (2001A); Yin, L. et al. (2001B); and Yin, L. et al. (2002). AA induces periportal liver injury, which is a liver injury model without the involvement of hepatocarcinogens (Peterson B.E. et al. (1998) *Hepatology* 27(4):1030-38). Five cell lines, named 1(1)#3, 1(1)#6, 1(3)#3, 2(11) and 3(8)#21, were chosen to investigate their potential of differentiation to pancreatic lineage cells. These 5 lines have been well characterized by Western blot, Northern blot, immunocytochemistry and histochemistry for various liver developmental, cell lineage markers and hematopoietic stem cell markers. The results are summarized in Figure 1. Pictures of the immunocytochemistry results of the line 3(8)#21 are also presented in Figure 1. Interestingly, almost all of the lines express hematopoietic stem cell markers CD34, Thy1.1, and CD45 indicating their possible relationship to hematopoietic stem cells. They also express liver progenitor cell genes such as α -fetal protein (AFP), albumin, cytokeratin 14 (CK14) and c-kit. They do not express Ito cell marker Desmin or Kupffer cell/macrophage markers, ED1 and ED2 (results not shown). These cells can be maintained in their undifferentiated status without the expression of mature hepatocyte-specific genes such as glucose-6-phosphatase (G-6-Pase), dipeptidyl peptidase IV (DPPIV), and cytochrome P450 (CYP450), and without showing the expression of mature bile duct cell-specific gene CK19 (results not shown). All 5 lines are diploid by flow cytometry. Induction of differentiation carried out in line 3(8)#21 shows that hepatocyte phenotype can be induced by long-term culture without STO fibroblast feeder layer (Figure 2 A, B). Basic FGF is able to augment the differentiation (Figure 2 C). Culturing the cells on matrigel induces liver bile duct phenotype (Figure 2 D, E). These results suggest bipotentiality of line 3(8)#21 to differentiate into hepatocytes or liver biliary cells.

Example 2 - Expression of pancreatic developmental and cell lineage specific genes in liver progenitor cell lines

These five (untreated) liver progenitor cell lines have been analyzed for the expression of selected pancreatic endocrine markers including insulin I and insulin II, pancreatic exocrine marker amylase, GLUT2 (glucose transporter), and some of the transcription factors that are critically involved in the development of pancreas such as *Pdx1*, *Isl1*, *NeuroD/β2*, *Nkx6.1* and *Pax4*. The expression of these genes was determined by RT-PCR, and confirmed by Southern blot. The data is presented in Figure 3. Rat pancreatic tissue expresses most of the markers tested including insulin I, insulin II, amylase, GLUT2, *Pdx1*, *Isl1*, and *Nkx6.1* but not *NeuroD/β2* and *Pax4* (Figure 3; lane 1). Gamma-irradiated STO feeder cells do not express any of these markers (Figure 3; lane 2). Liver progenitor cell lines 1(1)#3 (Figure 3; lane 3) and 3(8)#21 (Figure 3; lane 7) express almost all the pancreatic transcription factors tested and even insulin I and II, but they do not express detectable levels of amylase, *Pdx1* and GLUT2 (Figure 3; lanes 3 & 7). Cell line 1(1)#6 is positive for INSI and II and *NeuroD/β2* (Figure 3 lane 4). Cell line 2(11) are positive for *NeuroD/β2*, *Nkx6.1* and *Pax4* but negative for all other markers (Figure 3; lane 6). Cell line 1(3)#3 is only positive for *NeuroD/β2* (Figure 3; lane 5). These data indicate that at least 2 of the 5 liver progenitor lines (1(1)#3 and 3(8)21) tested express their "preparedness" to enter into pancreatic pathway even before any treatment with islet-differentiating factors.

Additionally, and as a positive control, the pancreas-determining transcription factor, *Pdx1* was transfected into each of these liver progenitor lines with the aim of directing the liver stem cells into pancreatic differentiation pathway. As shown in Figure 4, the introduction of *Pdx1* gene triggers the expression of amylase gene (Figure 4; lanes 3,5,7,9,11), which is not expressed in the non-transfected parental lines (Figure 4; lanes 2,4,6,8,10). Interestingly, cell lines 1(1)#3, and 3(8)#21 which express insulin II exhibit reduction of insulin II expression following transfection with *Pdx1* gene (Figure 4; lanes 2,3,10,11) while induction of insulin II was seen in cell lines that did not express the gene prior to transfection (Figure 4; lanes 4,5,6,7).

Example 3 - Characterization of expression in liver stem/progenitor cells under different experimental conditions so as to determine their differentiation potential

Liver progenitor lines described herein are studied for expression of genes controlling the pancreatic development at different stages (*Pdx1*, *Hlxb9*, *Isl1*, *ngn3*, *Nkx2.2*, *Pax6*,

NeuroD/β2, *Nkx6.1*, and *Pax4*), endocrine cell lineage markers (insulin I, insulin II, glucagon, somatostatin, and PP), exocrine markers (amylase and elastase), and the genes associated with insulin sensing, synthesis, process and secretion (GLUT-2, glucokinase, PC1, PC2, PC3 and carboxypeptidase E (CPE)). Each cell line is evaluated for expression under untreated and treated conditions. Treated cell lines are those that are grown under culture conditions known to enhance differentiation of pancreatic stem or progenitor cells, and/or are transfected with pancreatic development genes.

RT-PCR, Southern blot, immunocytochemistry, and Western blot techniques are used to determine the gene expression both at mRNA expression (all genes) and at protein levels (e.g. *Pdx1* and hormones). Normal pancreatic tissue, primary hepatocytes, and STO feeder cells serve as controls. The treated cell lines are characterized and compared to untreated lines. Expression of liver stem cell markers (AFP, albumin, CK14, c-kit, OV6, OV1) and hematopoietic stem/progenitor cell markers (CD34, Thy1.1, CD45) are also analyzed in the treated lines to see if their liver stem cell phenotypes are lost after treatment.

Plasmids such as plasmid pBKCMV/*Stf1* (*Pdx1*) carrying *Pdx1* gene and *Neo* gene (a gift from Dr. Dutta, Hoffmann-La Roche, Inc. Nutley, NJ), are used to transfect liver cell lines. The *Pdx1* transfected cells can be used as a positive control for differentiation into insulin-producing cells.

RT-PCR/Southern blot

DNA-free RNA is extracted by using StrataPrep™ Total RNA Miniprep Kit (Stratagene, La Jolla, CA) or RNAqueous™-4PCR Kit (Ambion, Austin, TX) by following the manufacture's protocol. RT-PCR is carried out following methods known in the art. The oligonucleotides used as amplimers for PCR are listed in Table 1. PCR cycle is at 95°C for 3 min followed by 94°C for 45 sec, corresponding optimized annealing temperature for each primer pair is 45 sec, 72°C for 1 min (34 cycles), and 72°C for 10 min. PCR products are run in 1.5% Seakem agarose gel in TBE buffer using a BioRad/RAC300 power supply at 100 volt for 80 min. The gel is incubated in 1% ethidium bromide solution in TBE buffer for 15 to 30 min, and then viewed using UV light. Image is photographed and processed using AlphaImage™2200 Documentation & Analysis system (Alpha Innotech Corporation, San Leandro, CA). Digoxigenin-labeling of an Oligo probe for Southern blotting is carried out by using Dig Oligonucleotide Tailing Kit (Roche Molecular Biochemicals, Indianapolis, IN) by

following the manufacture's protocol. As a corroborative technique, Southern blotting is carried out following the PCR reaction using the standard protocol.

Gene	Sense primer	Antisense primer	Size (bp)	GenBank accession number
<i>Pdx1</i>	ACATCTCCCATACGAAGTGCC	GGAGCTGGCAGTGATGCTCAACT	364	U04833(R)
<i>Isl1</i>	ACGTCTGATTTCCCTATGTGTTGG	CCGCTCTAAGGTGTACCACATCGA	276	S69329(R)
<i>Hlx9</i>	CAGCACCCGGCGCTCTCCTA	GAAGTGGTGCTCCAGCTCCAGCAGC	250	NM-005515(Hu)
<i>Ngn3</i>	CCTGCAGCTCAGCTGAACCTGGCGA	GCTCAGTGCCAACTCGCTCTT	485	AJ133776(Hu)
<i>Nkx2.2</i>	CCGAGAAAGGTATGGAGGTGAC	CTGGGCGTTGTACTGCATGTGCTG	187	X81408(Ha)
<i>Nkx6.1</i>	ATGGGAAGAGAAAACACACCAGAC	GAACGAGGAGGACGACGACGATTA	280	AF004431(R)
<i>Pax4</i>	TGGCTTTCTGCTCTCTGTGAGG	TCCAAGACTCCTGTGCGGTAGTAG	214	AF053100(R)
<i>Pax6</i>	AAGAGTGGCGACTCCAGAAGTTG	CCTGAAGCAAGGATACAGGTGTGGT	545	U69644(R)
<i>NeuroD/β2</i>	AGCCATGAATGCAGAGGAGGAC	ACACTCTGCAAAGGTTTGTC	400	AF107728(R)
Insulin I	ATGGCCCTGTGGATGCGCTT	CTGGAGAAGTACTGCAACT	331	J00747(R)
Insulin II	ATGGCCCTGTGGATCCGCTT	GTGACCTTCAGACCTTGGCA	243	V01243(R)
Glucagon	GTGGCTGGATTGTTGTAATGCTG	GTTGATGAACACCAAGAGGAACCG	236	NM-012707(R)
PP	TGAACAGAGGGCTCAATACGAAAC	GATTGTAGCCTCCCTCTGTCT	214	M18207(R)
Amylase	GCCTTGGTGGGAAAGATATC	TCCAAGGAAGCAGACCTTT	510	V01225(R)
Elastase	GTGAGCAGCCAGATGACTTTCC	CCTGGATGAACAATGTGATTG	573	NM-012552(R)
GLUT-2	TTAGCAACTGGGTCTGCAAT	CATGAGTGTAGGACTACACC	343	J03145(R)
Glucokinase	AGAGTGATGCTGGTCAAAGTGGGA	ATGATTGTGGGCACTGGCTGCAAT	440	J04218(R)
G3PDH	GCCATCACTGCCACCCAGAAG	GTCCACCACCCTGTTGCTGCA	440	M32599(R)

Table 3 Oligonucleotides used as amplimers for PCR. Ha, hamster; Hu, human; R, rat.

Immunocytochemistry

An avidin-biotin method adapted from Biogenex (San Ramon, CA) is followed. Cells are either cytospun onto Fisher Brand superfrost plus slides (Fisher Scientific, Pittsburgh, PA) using a cytocentrifuge (Cytopro™, Wescor, Inc. Logan, UT) or grown onto 8 well glass slides (ICN Costa Mesa, California) placed in tissue culture plates (Falcon®, Becton Dickinson, Franklin Lakes, NJ), and fixed in 0.5% glutaraldehyde for 1 hr at room temperature. For intracellular staining, the cells are permeabilized using 0.2% Triton-X. Blocking and antigen retrieval (when necessary) is done prior to primary antibody staining of the cells. Secondary antibodies are conjugated to biotin which is linked to alkaline phosphatase or horseradish peroxidase; and streptavidin, which binds to the biotin, is linked to alkaline phosphatase or peroxidase. Antibodies are then visualized using 3,3'-diaminobenzidine (DAB), 3-amino-9-ethylcarbazole (AEC), Fast Red, or 5-bromo-4-chloro-3-indolyl phosphate / nitro blue

tetrazolium (BCIP/NBT) . This system also can be used for double staining which can visualize multi-antigen expression.

Western blot

Western blot is also used for the gene translation study. Cells are lysed with lysis buffer (for 8.0 ml: 3.8 ml of dH₂O, 1 ml of 0.5 M Tris-HCl (pH 6.8), 0.8 ml of glycerol, 1.6 ml of 10% (w/v) SDS, and 0.4 ml of β -mercaptoethanol, and 0.4 ml of 0.5%

Basal Medium (BM) Components

DMEM (Dulbecco's Minimum Essential Medium, Gibco-BRL)
0.1mM 2-Mercaptoethanol
15% FBS (HyClone)
1x ITS (insulin, transferrin and selenium) (Gibco-BRL)
Penicillin 100IU/ml and streptomycin 100 μ g/ml
Fungizone® 1 μ g/ml (Gibco-BRL)
200mM L-glutamine
1X non-essential amino acids (Gibco-BRL)

Factors to be added to BM

Dexamethasone 10⁻⁷ M
GLP-1 (glucagon-like peptide) 10nM
Exendin-4 (10nM)
Gastrin (10nM)
IFN γ (interferon- γ) 0.1-2 ng/ml
HGF (hepatocyte growth factor) 20ng/ml
EGF (epidermal growth factor) 10ng/ml
Betacellulin 5nM
Activin A 1nM
KGF (keratinocyte growth factor) 5-10ng/ml
FGF (fibroblast growth factor) 10ng/ml
TGF- α (transforming growth factor) 10-15ng/ml
TGF- β
NGF (nerve growth factor) 25-50ng/ml
IGFs (insulin-like growth factor) 10ng/ml
INGAP (islet neogenesis associated protein) 125ng/ml
VEGF (vascular endothelial growth factor) 10-20ng/ml
Nicotinamide 10mM
Retinoic Acid 1ng/ml
Sodium butyrate 2.5mM

Table 4 Factors and their final concentrations in the medium

bromophenol blue). Tissues are homogenized on ice in homogenization buffer (20 mM Tris, 137 mM NaCl, 10% glycerol, 1 mM Na₃VO₄, 1 u/ml aprotinin, 1 mM 4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF), pH 8.0), centrifuged at 9,000 g for 20 min at 4°C, and the supernatant collected. The protein concentration is determined using Coomassie Plus Protein Assay Reagent (PIERCE, Rockford, Illinois). Samples are then run on separating gel at

appropriate concentration at 100 volts, 4 watts, and 50 mAs for 2 hr. Gel is then transferred using Mini Trans-Blot Cell (Bio-Rad, Hercules, CA) to nitrocellulose membrane (Bio-Rad) in transfer buffer (25 mM Tris, 192 mM glycine and 20% v/v methanol, pH 8.3) at 30 volts, 2 watts, and 50 mAs overnight. The membrane is then blotted in respective primary antibody at 4°C overnight. Thereafter, the membrane is washed and incubated with the corresponding secondary antibody linked with alkaline phosphatase for 1 hr at room temperature, and developed in carbonate buffer (0.1 M NaHCO₃, 1 mM MgCl₂, pH 9.8) containing 60 µl of nitro blue tetrazolium (NBT) solution (dissolve 50 mg of NBT in 0.7 ml of N,N-Dimethylformamide (DMF) with 0.3 ml dH₂O), and 60 µl of 5-bromo-4-chloro-3-indolyl phosphate (BCIP) solution (dissolve 50 mg of BCIP in 1 ml of 100% DMF) until appropriate color obtained.

Differentiation of liver stem cells

Liver stem cells are cultured in basal medium (BM) containing combinations of hormones (dexamethasone, GLP-1, exendin-4), growth factors (gastrin, interferon- γ (IGF γ), HGF, EGF, β -cellulin, activin-A, KGF, FGF, TGF- α & - β , NGF, IGFs, INGAP, and VEGF), vitamins (nicotinamide, and retinoic acid), and/or chemicals (sodium butyrate), at concentrations listed in Table 4. The concentrations set forth in Table 4 may be varied by 1-3 orders of magnitude so as to optimize their effectiveness. The foregoing hormones, growth factors, vitamins and chemicals are reported in the literature or in PCT Application No. PCT/US02/09881, filed March 29, 2002, to be involved in pancreas/ β -cell development. Expression of liver stem cells markers and hematopoietic stem cell markers are also observed in the treated lines to determine whether their liver stem cell phenotypes are lost after treatment.

Transfection and selection

FuGENE 6 transfection reagent (Roche Molecular Biochemicals, Indianapolis, IN) is used to transfect pBKCMV/*Stf1* (*Pdx1*) carrying *Pdx1* gene and Neogene into liver stem cell lines using manufacturer's protocol. Mock transfection and vector alone transfection are also done at the same time. Three days after gene transfection, the cells are cultured in the culture medium containing G418 1 mg/ml. The resistant clones are grown out in about ten days. The selection is carried out for 2 to 4 weeks. Thereafter, the cells are cultured in the culture medium containing 0.3 mg/ml of G418.

Analogous transfections can be carried out with plasmids containing other pancreatic development genes.

Example 4 - Determination of the functional capability of rat liver stem/progenitor cell-derived insulin-producing cells (LSDIPCs)

The cell lines of Example 3 that are found to produce insulin (LSDIPCs) are further evaluated for their glucose responsiveness. The cells are tested for both extra- and intracellular insulin production. Where a cell line demonstrates glucose responsive insulin production, then the substrate phosphorylation pattern can be determined following glucose stimulation. Freshly isolated rat islet cells serve as a positive control. Observation of substrate phosphorylation pattern reveals the early signaling events involved in the induction of insulin production.

Glucose induced insulin-stimulation assay

Differentiated LSDIPCs are seeded at a concentration of 2×10^5 cells per well in 24 well plates with 1 ml of medium containing 5.5 mM glucose for 24 hr to rest. Cells are washed with Krebs-Ringer buffer (KRB) and are stimulated with 1 ml of culture medium with or without glucose (0, 5.5, 11 and 17.5 mM glucose) for 3-18 hrs. The cell free supernatant is collected and stored at -70°C until use. The cells are then treated with lysis buffer to determine insulin content using Mercodia Ultrasensitive Rat Insulin ELISA Enzyme immunoassay kit (Mercodia, Uppsala, Sweden). This insulin kit is used to measure both secreted and intracellular insulin using BioRad's Benchmark plate reader (490nm). The insulin values are normalized to total DNA concentrations (extracted using TrizolTM, Gibco) of cells.

ELISAs for hormone detection

As mentioned above, secreted and intracellular insulin are measured using Mercodia Ultrasensitive Rat Insulin ELISA Enzyme immunoassay kit (Mercodia, Uppsala, Sweden) following the manufacturer's protocol. Similarly, a glucagon assay is carried out using methods known in the art or adaptations thereof.

Substrate phosphorylation assay

Differentiated LSDIPCs are homogenized in extraction buffer (20mmol/l K_2HPO_4 , pH 7.5, 5 mmol/l DTT, 1 mmol/l EDTA, and 110 mmol/l KCL) following stimulation with 17.5

mM glucose for 0, 5, 15 and 30 min. The homogenate is used to separate protein on 10% SDS-PAGE (BioRad) and the phosphorylated protein substrates are detected using anti-phosphotyrosine antibody (Pharmingen, San Diego, CA) in Western blot technique.

It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.

Claims

1. A method of converting a liver stem/progenitor cell to a pancreatic functional cell, wherein said pancreatic functional cell produces and secretes insulin in response to glucose stimulation, said method comprising:
transfecting said liver stem/progenitor cell with a pancreatic development gene, culturing said liver stem/progenitor cell in a medium comprising factors that induce differentiation into the pancreatic functional cell, or both, whereby said transfected cell is converted to the pancreatic functional cell.
2. The method of claim 1, wherein the pancreatic functional cell is a cell of the pancreatic endocrine lineage.
3. The method of claim 2, wherein said converted cell is selected from the group consisting of islet producing stem cells (IPSCs), islet progenitor cells (IPCs) and islet-like structures or IPC-derived islets (IdIs).
4. The method of claim 1, wherein the pancreatic functional cell further expresses a marker of the liver stem/progenitor cell.
5. The method of claim 1, wherein said liver stem/progenitor cell is selected from the group consisting of hepatoblasts and liver oval cells.
6. The method of claim 1, wherein said liver stem/progenitor cell expresses at least one marker selected from the group consisting of hematopoietic markers and liver oval or hepatoblast cell markers.
7. The method of claim 6, wherein said hematopoietic markers are selected from the group consisting of CD34, Thy1.1 and CD45.
8. The method of claim 6, wherein said liver hepatoblast or oval cell markers are selected from the group consisting of α -fetal protein, albumin, cytokeratin 14 (CK14), c-kit, OC.2, OC.3, OC.10, OV1 and OV6.

9. The method of claim 1, wherein said pancreatic development gene is selected from the group consisting of *Pdx1*, *Hlxb9*, *Isl1*, *ngn3*, *Nkx2.2*, *Pax6*, *NeuroD/β2*, *Nkx6.1* and *Pax4*.
10. The method of claim 9, wherein said pancreatic development gene is *Pdx-1*.
11. The method of claim 1, wherein said factors are selected from the group consisting of dexamethasone, glucagon-like peptide-1 (GLP-1), exendin-4, gastrin, interferon- γ (IFN γ), hepatocyte growth factor (HGF), epidermal growth factor (EGF), β -cellulin, activin-A, keratinocyte growth factor (KGF), fibroblast growth factor (FGF), transforming growth factor- α (TGF- α), transforming growth factor- β (TGF- β), nerve growth factor (NGF), insulin-like growth factors (IGFs), islet neogenesis associated protein (INGAP), vascular endothelial growth factor (VEGF), nicotinamide, retinoic acid, sodium butyrate and any combination thereof.
12. The method of claim 1, wherein said converted cell expresses a pancreatic message selected from the group consisting of insulin I (InsI), insulin II (InsII), glucagon, somatostatin, pancreatic polypeptide (PP), amylase, elastase, glucose transporter 2 (GLUT2), glucokinase, PC1, PC2, PC3, carboxypeptidase E (CPE), *Pdx1*, *Hlxb9*, *Isl1*, *ngn3*, *Nkx2.2*, *Pax6*, *NeuroD/β2*, *Nkx6.1* and *Pax4*.
13. The method of claim 1, wherein said converted cell expresses a pancreatic protein selected from the group consisting of InsI, InsII, glucagon, somatostatin, PP, amylase, elastase, GLUT2, glucokinase, PC1, PC2, PC3, CPE, *Pdx1*, *Hlxb9*, *Isl1*, *ngn3*, *Nkx2.2*, *Pax6*, *NeuroD/β2*, *Nkx6.1* and *Pax4*.
14. A pancreatic functional cell produced by the method of claim 1.
15. The pancreatic functional cell of claim 14, wherein the cell further expresses *Pdx1*, amylase and insulin II.
16. A method for producing an endocrine hormone comprising converting liver stem/progenitor cells according to the method of claim 1, and further comprising:
culturing said converted cells; and

recovering endocrine hormone from said cell culture.

17. A liver stem/progenitor cell that has been transfected with a pancreatic development gene.
18. The method of claim 17, wherein said liver stem/progenitor cell is selected from the group consisting of hepatoblasts and liver oval cells.
19. The liver stem/progenitor cell of claim 17 wherein the pancreatic development gene is selected from the group consisting of *Pdx1*, *Hlxb9*, *Isl1*, *ngn3*, *Nkx2.2*, *Pax6*, *NeuroD/β2*, *Nkx6.1* and *Pax4*.
20. The liver stem/progenitor cell of claim 19 wherein the pancreatic development gene is *Pdx1*.
21. A liver stem/progenitor cell that has been cultured in a medium comprising factors that induce differentiation into a pancreatic functional cell.
22. The liver stem/progenitor cell of claim 21 wherein said factors are selected from the group consisting of dexamethasone, glucagon-like peptide-1 (GLP-1), exendin-4, gastrin, interferon-γ (IFNγ), hepatocyte growth factor (HGF), epidermal growth factor (EGF), β-cellulin, activin-A, keratinocyte growth factor (KGF), fibroblast growth factor (FGF), transforming growth factor-α (TGF-α), transforming growth factor-β (TGF-β), nerve growth factor (NGF), insulin-like growth factors (IGFs), islet neogenesis associated protein (INGAP), vascular endothelial growth factor (VEGF), nicotinamide, retinoic acid, sodium butyrate and any combination thereof.






		1(1)#3	1(1)#6	1(3)#3	2(11)	3(8)#21
Liver progenitor cell markers	AFP	+	+	-	++	+
	Albumin	+	+	-	++	+
		+	+	+	+/-	+
	CK14					
		+	-	+	+	+
	c-kit					
hematopoietic stem cell markers		+	+	+	+	+
	CD34					
		+	+	+	+	+
	Thy1.1					
		-	+	+	+	+
	CD45					

Figure 1




Figure 2




Figure 3




Figure 4

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/33304

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 15/09, 5/02; C12P 21/06;

US CL : 435/455, 325, 69.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/455, 325, 69.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EAST, BIOSIS, CAPLUS, CANCERLET, EMBASE, SCISEARCH, MEDLINE**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FERBER, S. et al. Pancreatic and duodenal homeobox gene 1 induces expression of	17, 19-22
---	insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia. Nat. Med.	-----
Y	2000 May, Vol. 6, No. 5, pages 568-572. See particularly figure 2, and the paragraph in	1-16
	the right column of page 570.	
Y	US 2001/0013134 A1 (SARVETNICK ET AL) 9 AUGUST 2001(09.08.2001). See	1-16
	abstract.	
X, P	YANG, L. et al. In vitro trans-differentiation of adult hepatic stem cells into pancreatic	1-17, 19-22
	endocrine hormone-producing cells. PNAS. 11 June 2002, Vol. 99, No. 12, pages 8078-	
	8083. See entire document.	

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

21 February 2003 (21.02.2003)

Date of mailing of the international search report

13 MAR 2003

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks

Box PCT

Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Q. Janice Li

Telephone No. 703-308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/33304

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claim Nos.: 18
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Claim 18 recites the limitation "the method of claim 17", there is insufficient antecedent basis for this limitation in the claim.
3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

THIS PAGE BLANK (USPTO)

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**

THIS PAGE BLANK (USPTO)